Correlation Engine 2.0
Clear Search sequence regions


Sizes of these terms reflect their relevance to your search.

The CROWN study suggests that lorlatinib is effective in patients newly diagnosed with advanced ALK-positive non-small cell lung cancer. In the phase III trial, patients treated with lorlatinib were twice as likely to be alive without disease progression after 1 year than those who received crizotinib-with slower progression of brain metastases. ©2020 American Association for Cancer Research.

Citation

Lorlatinib Outperforms Crizotinib in NSCLC. Cancer discovery. 2021 Jan;11(1):OF5

Expand section icon Mesh Tags

Expand section icon Substances


PMID: 33298467

View Full Text